165 related articles for article (PubMed ID: 33037136)
21. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
24. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
[TBL] [Abstract][Full Text] [Related]
25. Yeast eukaryotic initiation factor 4B (eIF4B) enhances complex assembly between eIF4A and eIF4G in vivo.
Park EH; Walker SE; Zhou F; Lee JM; Rajagopal V; Lorsch JR; Hinnebusch AG
J Biol Chem; 2013 Jan; 288(4):2340-54. PubMed ID: 23184954
[TBL] [Abstract][Full Text] [Related]
26. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
[TBL] [Abstract][Full Text] [Related]
27. Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI.
Zakowicz H; Yang HS; Stark C; Wlodawer A; Laronde-Leblanc N; Colburn NH
RNA; 2005 Mar; 11(3):261-74. PubMed ID: 15661843
[TBL] [Abstract][Full Text] [Related]
28. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
29. Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence.
Raza F; Waldron JA; Quesne JL
Biochem Soc Trans; 2015 Dec; 43(6):1227-33. PubMed ID: 26614665
[TBL] [Abstract][Full Text] [Related]
30. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
31. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.
Chu J; Galicia-Vázquez G; Cencic R; Mills JR; Katigbak A; Porco JA; Pelletier J
Cell Rep; 2016 Jun; 15(11):2340-7. PubMed ID: 27239032
[TBL] [Abstract][Full Text] [Related]
32. Monitoring RNA restructuring in a human cell-free extract reveals eIF4A-dependent and eIF4A-independent unwinding activity.
O'Sullivan MH; Fraser CS
J Biol Chem; 2023 Jul; 299(7):104936. PubMed ID: 37331603
[TBL] [Abstract][Full Text] [Related]
33. FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation.
Nguyen TM; Kabotyanski EB; Dou Y; Reineke LC; Zhang P; Zhang XH; Malovannaya A; Jung SY; Mo Q; Roarty KP; Chen Y; Zhang B; Neilson JR; Lloyd RE; Perou CM; Ellis MJ; Rosen JM
Cancer Res; 2018 Aug; 78(15):4229-4240. PubMed ID: 29844125
[TBL] [Abstract][Full Text] [Related]
34. eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes.
Waldron JA; Raza F; Le Quesne J
Nucleic Acids Res; 2018 Apr; 46(6):3075-3087. PubMed ID: 29471358
[TBL] [Abstract][Full Text] [Related]
35. WD Repeat Domain 77 Protein Regulates Translation of E2F1 and E2F3 mRNA.
Altayyar MA; Sheng X; Wang Z
Mol Cell Biol; 2020 Nov; 40(24):. PubMed ID: 33020149
[TBL] [Abstract][Full Text] [Related]
36. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.
Kayastha F; Herrington NB; Kapadia B; Roychowdhury A; Nanaji N; Kellogg GE; Gartenhaus RB
Mol Med; 2022 Sep; 28(1):101. PubMed ID: 36058921
[TBL] [Abstract][Full Text] [Related]
37. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.
Wolfe AL; Singh K; Zhong Y; Drewe P; Rajasekhar VK; Sanghvi VR; Mavrakis KJ; Jiang M; Roderick JE; Van der Meulen J; Schatz JH; Rodrigo CM; Zhao C; Rondou P; de Stanchina E; Teruya-Feldstein J; Kelliher MA; Speleman F; Porco JA; Pelletier J; Rätsch G; Wendel HG
Nature; 2014 Sep; 513(7516):65-70. PubMed ID: 25079319
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
[TBL] [Abstract][Full Text] [Related]
40. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
